Cannabis use disorder is increasingly common as legalization expands and cannabis products diversify. Modern cannabis products (concentrates, edibles, vape pens) deliver substantially higher THC potency than historical cannabis — THC content in commercial flower products has roughly tripled in the past two decades, with concentrates exceeding 80% THC.
The diagnosis is real and not controversial. Despite cultural narratives that cannabis is non-addictive, DSM-5 cannabis use disorder occurs in approximately 30% of regular cannabis users. Tolerance develops, withdrawal occurs, compulsive use patterns emerge, and substantial functional impairment is common. Many patients describe their cannabis use as "not a problem" while meeting multiple SUD criteria.
Cannabis withdrawal is real (recognized in DSM-5 since 2013): irritability, anxiety, sleep disturbance (often with vivid dreams), decreased appetite, restlessness, depressed mood, physical symptoms (headache, sweating). Onset within 24-72 hours of cessation, peaks at days 2-6, resolves over 1-2 weeks. Often surprises patients who didn't expect withdrawal from cannabis.
Adolescent cannabis use carries elevated risks. The developing brain — particularly the endocannabinoid system involved in synaptic pruning and cortical maturation — is vulnerable to chronic CB1 activation. Heavy adolescent use is associated with: increased risk of psychotic disorders in genetically vulnerable individuals (with the risk dose-dependent and higher with high-potency products), persistent cognitive effects (working memory, processing speed), increased risk of progressing to SUD, increased risk of cannabis-induced acute psychotic episodes.
Cannabis hyperemesis syndrome is an underrecognized complication of chronic heavy use: cyclic episodes of severe nausea and vomiting, often relieved by hot showers (compulsive hot showering is pathognomonic), resolves with sustained cannabis abstinence. Often misdiagnosed for years; recognition often comes after multiple ED visits.
Treatment: no FDA-approved pharmacotherapy for cannabis use disorder. N-acetylcysteine 1200 mg twice daily has emerging evidence in adolescents. Gabapentin has some evidence. Behavioral interventions are the foundation: motivational enhancement therapy, CBT for cannabis use disorder, contingency management.
Counseling considerations: acknowledge cannabis use is common and that legal does not mean safe; explain age-specific risks (particularly adolescent brain vulnerability); discuss family history of psychotic illness if present; use motivational interviewing rather than confrontation; address comorbid mental health conditions that may drive self-medication.
When you encounter a patient with cannabis use disorder, the diagnosis is real and the treatment is behavioral. The cultural minimization of cannabis-related harms is gradually shifting as research accumulates. Particularly for adolescents and patients with psychotic vulnerability, structured engagement is appropriate.